Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to reduce radiation side effects for women with gynecologic cancers

NCT ID NCT07415681

Symptom relief Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This study compares two standard radiation methods—proton therapy and photon therapy—for women with newly diagnosed cervical or endometrial cancer. The goal is to see which approach causes fewer stomach and bowel side effects. About 116 participants will be randomly assigned to one of the two treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 116 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Dec 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. a. Newly diagnosed endometrial cancer after TAH/BSO and nodal sampling, sentinel LN biopsy or pelvic nodal dissection planning to receive sequential chemotherapy and radiation or concurrent chemoradiotherapy or b. cervical cancer planning to receive definitive chemoradiation with HDR brachytherapy boost 2. Histologic confirmation of malignancy (primary only) 3. ≥ 18 years of age 4. ECOG performance status ≤ 2 5. Patient must have the ability to understand and the willingness to sign a written informed consent document or when appropriate, have an acceptable surrogate capable of giving consent on the subject's behalf. 6. Insurance approval for IMPT Exclusion Criteria: 1. Metastatic disease beyond para-aortic lymph nodal region 2. Residual tumor after surgery exceeding 2 cm in maximum dimension in patients with endometrial cancer. 3. FIGO 2014 stage III-IVA cervix cancer planning to receive concurrent pembrolizumab. 4. Cervical cancer with inability to receive concurrent chemotherapy. 5. Any prior pelvic radiation. 6. Treatment with other investigational agents. 7. Carcinosarcoma. 8. Creatine clearance \<30 mL/m2 9. Unable to lie flat during or tolerate radiation. 10. Refusal to sign informed consent. 11. Any additional active cancer that would interfere with the primary study endpoints

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer endometrial cancer female reproductive organ cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer Gynaecologic cancer Radiation therapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    5 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baltimore Washington Medical Center- Tate Cancer Center

    RECRUITING

    Glen Burnie, Maryland, 21061, United States

  • Central Maryland Radiation Oncology

    RECRUITING

    Columbia, Maryland, 21044, United States

  • Maryland Proton Treatment Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • University of Maryland Greenebaum Cancer Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • Upper Chesapeake Health

    RECRUITING

    Bel Air, Maryland, 21014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.